Thomas Baker

938 total citations
40 papers, 692 citations indexed

About

Thomas Baker is a scholar working on Genetics, Surgery and Epidemiology. According to data from OpenAlex, Thomas Baker has authored 40 papers receiving a total of 692 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 8 papers in Surgery and 8 papers in Epidemiology. Recurrent topics in Thomas Baker's work include Inflammatory Bowel Disease (12 papers), Eosinophilic Esophagitis (6 papers) and Microscopic Colitis (5 papers). Thomas Baker is often cited by papers focused on Inflammatory Bowel Disease (12 papers), Eosinophilic Esophagitis (6 papers) and Microscopic Colitis (5 papers). Thomas Baker collaborates with scholars based in United States, United Kingdom and Italy. Thomas Baker's co-authors include Michael J. Satlin, David J. Procter, Tsuyoshi Nakamura, K. C. Nicolaou, Christopher J. O’Brien, David J. Edmonds, Yen‐Lin Chen, Swapnil K. Sonkusare, Carmen López and Mark H. Stefaniak and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Angewandte Chemie International Edition.

In The Last Decade

Thomas Baker

39 papers receiving 679 citations

Peers

Countries citing papers authored by Thomas Baker

Since Specialization

Citations

This map shows the geographic impact of Thomas Baker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Baker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Baker more than expected).

Fields of papers citing papers by Thomas Baker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Baker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Baker. The network helps show where Thomas Baker may publish in the future.

Co-authorship network of co-authors of Thomas Baker

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Baker. A scholar is included among the top collaborators of Thomas Baker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Baker. Thomas Baker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	OP10 Efficacy and safety of subcutaneous guselkumab induction therapy in patients with Ulcerative Colitis: Results through week 12 from the phase 3 ASTRO study 2025 ·Journal of Crohn s and Colitis ·Laurent Peyrin‐Biroulet, Jessica R. Allegretti, Silvio Danese, Matthew Germinaro, Thomas Baker, Yolanda Álvarez, Silke Jörgens, (unknown), Hui Zhang, Takashi Hisamatsu, David T. Rubin, (unknown)	6
2	P0608 Safety of guselkumab in Inflammatory Bowel Disease up to 1 year: Integrated safety analysis of phase 2 and 3 studies in Crohn’s Disease and Ulcerative Colitis 2025 ·Journal of Crohn s and Colitis ·B E Sands, Remo Panaccione, Silvio Danese, Julián Panés, Takashi Hisamatsu, Geert D’Haens, Rian Van Rampelbergh, Mobolaji Olurinde, Jacqueline Yee, Thomas Baker, Shadi Yarandi, Matthew Germinaro, Monica L. Vetter, Li Huang, (unknown), Jessica R. Allegretti, Anita Afzali, David T. Rubin	1
3	P436 Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn’s disease patients with secondary loss of response to ustekinumab maintenance therapy: Week 16 results from the POWER trial 2023 ·Journal of Crohn s and Colitis ·S Schreiber, (unknown), C. Janneke van der Woude, Ignacio Marín‐Jiménez, Douglas C. Wolf, Elisabeth Schnoy, Bruce Salzberg, (unknown), (unknown), Wayne Langholff, (unknown), C Gasink, Thomas Baker, (unknown), B G Feagan, (unknown)	8
4	P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications 2023 ·Journal of Crohn s and Colitis ·Subrata Ghosh, (unknown), Elyssa Ott, C Gasink, Thomas Baker, (unknown), Yi Miao, Edward V. Loftus	1
5	1027 EFFICACY AND SAFETY OF INTRAVENOUS USTEKINUMAB REINDUCTION THERAPY IN CROHN'S DISEASE PATIENTS WITH SECONDARY LOSS OF RESPONSE TO USTEKINUMAB MAINTENANCE THERAPY: WEEK 16 RESULTS FROM THE POWER TRIAL 2023 ·Gastroenterology ·Scott D. Lee, Stefan Schreiber, C. Janneke van der Woude, Ignacio Marín‐Jiménez, Douglas C. Wolf, Elisabeth Schnoy, Bruce Salzberg, (unknown), (unknown), Wayne Langholff, (unknown), Christopher Gasink, Thomas Baker, (unknown), Brian G. Feagan	3
6	A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn’s Disease 2023 ·Journal of Crohn s and Colitis ·Matthieu Allez, Bruce E. Sands, Brian G. Feagan, Geert D’Haens, Gert De Hertogh, Charles Randall, Bin Zou, Jewel Johanns, Christopher O’Brien, Mark Curran, (unknown), Mei‐Lun Wang, (unknown), Thomas Baker, Taku Kobayashi	5
7	S903 Cumulative Response to Guselkumab Through Week 24 of Induction in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study 2023 ·The American Journal of Gastroenterology ·David T. Rubin, Bruce E. Sands, Gary R. Lichtenstein, Thomas Baker, Kuan‐Hsiang Gary Huang, Matthew Germinaro, Miao Ye, Hongyan Zhang, Stéphane Nancey, Jessica R. Allegretti, Brian G. Feagan, Tadakazu Hisamatsu, Julián Panés, Axel Dignaß, Brian Bressler, Laurent Peyrin‐Biroulet	1
8	Caveolar peroxynitrite formation impairs endothelial TRPV4 channels and elevates pulmonary arterial pressure in pulmonary hypertension 2021 ·Proceedings of the National Academy of Sciences ·Zdravka Daneva, Corina Marziano, Matteo Ottolini, Yen‐Lin Chen, Thomas Baker, (unknown), (unknown), Huy Q. Ta, (unknown), Andrew D. Mihalek, Ramesh B. Kasetti, Yuanjun Shen, Brant E. Isakson, Richard D. Minshall, Gulab Zode, Elena A. Goncharova, Victor E. Laubach, Swapnil K. Sonkusare	60
9	Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA–a retrospective study of claims data from 2009 to 2020 2021 ·Clinical Rheumatology ·Joseph F. Merola, (unknown), Soumya D. Chakravarty, (unknown), L. Mesana, (unknown), (unknown), M. Shawi, Maud Pacou, Thomas Baker, (unknown)	18
10	Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies 2020 ·Inflammatory Bowel Diseases ·William J. Sandborn, Brian G. Feagan, Silvio Danese, Christopher D. O’Brien, Elyssa Ott, Colleen Marano, Thomas Baker, Yiying Zhou, Sheri Volger, Ilia Tikhonov, Christopher Gasink, Bruce E. Sands, Subrata Ghosh	77
11	Blastomycosis during pregnancy: a case report and review of the literature 2017 ·Diagnostic Microbiology and Infectious Disease ·Thomas Baker, Ami Patel, (unknown), Sima S. Toussi, Patricia DeLaMora, Shari R. Lipner, Audrey N. Schuetz, Barry J. Hartman	6
12	Hyperspectral imaging fluorescence excitation scanning for detecting colorectal cancer: pilot study 2016 ·Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE ·Silas J. Leavesley, (unknown), Carmen López, Thomas Baker, Peter F. Favreau, Thomas C. Rich, (unknown), Carole Boudreaux	8
13	The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies 2016 ·Leukemia & lymphoma ·Thomas Baker, Michael J. Satlin	43
14	Characterization of Piperacillin-Tazobactam–Non-Susceptible, but Ceftriaxone-Susceptible, Escherichia coli and Klebsiella pneumoniae Bloodstream Infections 2016 ·Open Forum Infectious Diseases ·Thomas Baker, David P. Calfee, Lars F. Westblade, Stephen G. Jenkins, Barry N. Kreiswirth, Michael J. Satlin	1
15	A delayed presentation of Boerhaave's syndrome with mediastinitis managed using the over-the-scope clip 2013 ·Journal of Surgical Case Reports ·(unknown), (unknown), Shameen Jaunoo, Thomas Baker, Jayan Mannath, James J. Harding, Vinod Menon	14
16	A Review of Antithrombotic Therapy for Transcatheter Aortic Valve Replacement 2013 ·Postgraduate Medicine ·(unknown), (unknown), Thomas Baker	2
17	Cost-Effectiveness of Linezolid vs Vancomycin in Suspected Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia in Germany 2009 ·Infection ·E De Cock, Wolfgang A. Krueger, (unknown), Thomas Baker, (unknown), S Duttagupta, E. Müller, (unknown), Emil C. Reisinger, Ansgar Resch	33
18	Cost-efficacy analysis of biological treatments in psoriasis: an 18-month assessment 2005 ·Journal of Medical Economics ·Alan Menter, Thomas Baker	5
19	The association between telomerase, p53, and clinical staging in colorectal cancer 1998 ·The American Journal of Surgery ·Tommy A. Brown, Wade K. Aldous, Raymond Lance, (unknown), Thomas Baker, William Williard, (unknown)	27
20	Chemical face peeling: an adjunct to surgical facelifting. 1963 ·PubMed ·Thomas Baker, (unknown)	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact